ClinicalTrials.gg
RecruitingNCT07548177Updated Nov 16, 2026

Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma

A Phase 2 interventional study of Benmelstobart injection combined with Anlotinib hydrochloride capsule in Alveolar Soft Part Sarcoma, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 15 sites in China. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 16, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
14 Years and older
Sex
All
01

Study summary

This is a Phase II, single-arm, multicenter clinical study aimed at demonstrating the effectiveness of benmelstobart injection combined with anlotinib hydrochloride capsules in patients aged 14 years or older with advanced or unresectable alveolar soft part sarcoma by evaluating the objective response rate (IRC).

02

Conditions studied

  • Alveolar Soft Part Sarcoma
03

In context

Sarcoma, Alveolar Soft Part

51 studies on the registry are indexed under Sarcoma, Alveolar Soft Part; 10 are open to participants now.

This study's planned enrollment of 33 is below the median of 53 across 49 interventional studies indexed under Sarcoma, Alveolar Soft Part.

Browse Sarcoma, Alveolar Soft Part studies →

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Only when all the following criteria are met will the subjects be eligible for inclusion in this study:

    1. The subjects voluntarily join this study, sign the form, and have good compliance;
    2. ≥14 years old (calculated from the date of signing the informed consent form);
    3. Performance Status (ECOG) score of 0 to 1;
    4. Expected survival greater than 12 weeks;
    5. confirmed recurrent and/or or unresectable alveolar soft part sarcoma, without previous systemic treatment;
    6. Confirmed to have at least one according to 1.1;
    7. Laboratory tests meet the following standards (No hematopoietic stimulating factors have been used for correction within the past 14 days):

      1. (HGB) ≥ 90g/L;
      2. (NEUT) ≥ 1.5×109/L;
      3. count (PLT) ≥ 100×109/L.
      4. Total (TBIL) ≤ 1.5 times the (ULN);
      5. (ALT) and aspartate aminotransferase (AST) ≤ 2.5 ULN. If there is liver metastasis, ALT and AST ≤ 5 ULN;
      6. Serum creatinine (CR) ≤ 1.5 ULN or rate (CCR) ≥ 60ml/min;
      7. (PT), activated partial thromboplastin time (APTT), and international normalized ratio (INR) ≤ 1.5×ULN (if not receiving anticoagulant therapy);
      8. Thyroid stimulating hormone (TSH) ≤ ULN; if abnormal, T3 and T4 levels should be examined. If T3 and T4 levels are normal, the subject can be included.
    8. Women of childbearing age must agree to use effective measures during the study and for 6 months after the study, and have a negative serum test within 7 days before study enrollment; men must agree to use effective contraceptive measures during the study and for 6 months after the study.

Exclusion criteria

Exclusion Criteria:

  • Any subject meeting any of the following criteria will be excluded from this trial:

    1. Having had or currently having another malignant tumor within 5 years before the first administration of the drug. The following two situations are eligible for inclusion: other malignant tumors treated with a single surgery and achieving a disease-free survival (DFS) of at least 5 consecutive years; cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading the basement membrane)].
    2. Having diseases that affect intravenous injection or blood collection, or having multiple factors that affect oral medication (such as inability to swallow, chronic diarrhea, and intestinal obstruction, etc.).
    3. Adverse reactions from previous treatments have not recovered to a (CTCAE) v5.0 grade score of ≤1, except for grade 2 alopecia, grade 2 peripheral neuropathy, grade 2 anemia, non- and asymptomatic laboratory abnormalities, and stable hypothyroidism treated with hormone replacement therapy, which are judged by the investigator to have no safety risks.
    4. Having undergone major surgery, significant traumatic injury, or expected to undergo major surgery during the study period within 4 weeks before the first administration of the drug (except for surgeries specified in the protocol), or having long-term unhealed wounds or fractures. (Major surgery is defined as: surgeries classified as grade 3 or above in the 2023 version of the surgical classification directory of the participating center).
    5. Having experienced any bleeding or hemorrhagic event ≥ CTCAE grade 3 within 4 weeks before the first administration of the drug.
    6. Having experienced an arterial or venous thrombotic event within 6 months before the first administration of the drug, such as cerebrovascular accident (including ), deep vein thrombosis, and pulmonary embolism.
    7. Active viral hepatitis that is not well controlled. Subjects meeting the following requirements can be screened: -positive subjects must have Hepatitis B Virus (HBV) DNA quantification \< 2000 IU/ml (or 1*104 copies/ml) or have received at least 1 week of antiviral treatment for HBV before the start of the study and have a 10-fold (1 log value) or greater reduction in viral index, and be willing to receive antiviral treatment throughout the study; -infected subjects (HCV Ab or HCV RNA positive): judged by the investigator to be in a stable state or receiving antiviral treatment at the time of enrollment and continuing to receive approved antiviral treatment during the study.
    8. Active syphilis infection requiring treatment.
    9. Having active tuberculosis, a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonia, radiation pneumonitis requiring treatment, or active pneumonia with clinical symptoms.
    10. Having a history of substance abuse of psychotropic drugs and being unable to quit or having a mental disorder.
    11. Preparing for or having previously received bone marrow transplantation or solid organ transplantation.
    12. Having major cardiovascular diseases, including any of the following conditions:

      1. Cardiac insufficiency of Functional Classification (NYHA) class II or above or echocardiography showing (LVEF) \< 50%;
      2. History of clinically significant ventricular arrhythmias (such as sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes ventricular tachycardia) or arrhythmias requiring continuous antiarrhythmic drug treatment;
      3. Unstable angina pectoris;
      4. Myocardial infarction within 12 months;
      5. Fridericia- interval (QTcF) > 450 milliseconds (msec) for men and > 470 msec for women (if QTc is abnormal, it can be continuously measured three times with an interval of more than 2 minutes, and the average value is taken);
      6. History or family history of congenital long QT syndrome. 7) A history of deep vein thrombosis, pulmonary embolism or any other serious thromboembolic event within 3 months prior to randomization (implantable venous access ports or catheter-related thrombosis, or superficial venous thrombosis are not considered "serious" thromboembolic events);
      7. Currently using or having used within 7 days prior to the start of study treatment aspirin (>325 mg/day (maximum antiplatelet dose)), dipyridamole, ticlopidine, clopidogrel, or cilostazol;
    13. Active or uncontrolled severe infection (≥CTC AE grade 2 infection);
    14. Renal failure requiring hemodialysis or peritoneal dialysis;
    15. History of immunodeficiency, including positivity or other acquired or congenital immunodeficiency diseases;
    16. Subjects who need to use , systemic or absorbable local hormones for immunosuppression purposes and will continue to do so within 7 days before the first administration (except for at a daily dose of \<10 mg prednisone or other equivalent efficacy hormones);
    17. Patients with epilepsy requiring treatment;
    18. Tumor-related symptoms and treatment:

      1. Having received treatment with traditional Chinese patent medicines with clear anti-tumor indications in the National Medical Products Administration (NMPA)-approved drug instructions (including Compound Cantharidin Capsules, Kang'ai Injection, Kanglaite Capsules/Injection, Aidi Injection, Brucea javanica Oil Injection/Capsules, Xiaoaiping Tablets/Injection, Chan Su Capsules, etc.) within 2 weeks prior to the start of study treatment;
      2. Having received previous treatment with targeting PD-1, PD-L1, or Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4);
      3. Having previously used anti-angiogenic drugs such as bevacizumab, anlotinib, apatinib, lenvatinib, sorafenib, sunitinib, regorafenib, or fruquintinib;
      4. Having received treatment with drugs with immunomodulatory functions (such as interleukin-2, thymosin, polysaccharides from Lentinus edodes, etc.) within 30 days prior to the start of treatment;
      5. Not having recovered from the toxicity and/or complications of previous interventions to CTCAE ≤ grade 1, except for alopecia and peripheral neuropathy ≤ grade 2. ;
      6. Imaging studies (CT or MRI) show that the tumor has invaded major blood vessels or the investigator deems that the tumor is highly likely to invade major blood vessels and cause fatal hemorrhage during the subsequent study period;
      7. Uncontrolled pleural effusion, pericardial effusion or moderate to severe ascites (as judged by the investigator) that requires repeated drainage;
      8. Known spinal cord compression, carcinomatous meningitis, symptomatic , or brain metastases with less than 4 weeks of symptomatic/radiographic control.
    19. Known to be allergic to the of the study drug.
    20. Participants who have taken part in and used other anti-tumor clinical trial drugs within 4 weeks before the first administration of the study drug.
    21. As judged by the investigator, there are serious conditions that endanger the safety of the participant or affect the participant's completion of the study.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    Benmelstobart injection+Anlotinib Hydrochloride Capsules

    Benmelstobart injection combined with Anlotinib hydrochloride capsules, with a 21-day cycle.

    Drug: Benmelstobart injection combined with Anlotinib hydrochloride capsule

Interventions

  • DrugBenmelstobart injection combined with Anlotinib hydrochloride capsule

    Drug pages: Benmelstobart · Catequentinib hydrochloride

    Benmelstobart is a PD-L1 immunosuppressant. Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.

06

What researchers measure

Primary outcomes

  1. Objective response rate (IRC assessment)

    The proportion of patients with tumor volume reduction reaching 30% is usually the sum of the proportions of complete response (CR) and partial response (PR). (IRC Assessment)

    Time frame: The period from baseline to the end of the trial is expected to be 32 months.

Secondary outcomes

  1. Disease control rate (IRC assessment)

    The proportion of cases that achieved remission (CR+PR) and disease stability (SD) after treatment, that is, the proportion of patients who did not experience disease progression (PD). (IRC Assessment)

    Time frame: The period from baseline to the end of the trial is expected to be 32 months.

  2. Duration of remission (IRC assessment)

    The duration from the first significant shrinkage of the tumor to its subsequent enlargement/progression (IRC assessment)

    Time frame: The period from baseline to the end of the trial is expected to be 32 months.

  3. Progression-free survival (IRC assessment)

    From the time of random initiation to the occurrence of a predetermined event, an event may include death, disease progression, change to chemotherapy, change to chemotherapy, addition of other treatments, occurrence of fatal or intolerable side effects, etc.(IRC assessment)

    Time frame: The period from baseline to the end of the trial is expected to be 32months.

  4. 12-month progression-free survival rate (IRC assessment)

    The proportion of subjects whose condition did not deteriorate or progress from the start of treatment to 12 months (IRC assessment)

    Time frame: From baseline to 12 months after treatment

  5. 24-month progression-free survival rate (IRC assessment)

    The proportion of subjects whose condition did not deteriorate or progress from the start of treatment to 24 months (IRC assessment)

    Time frame: From baseline to 24 months after treatment

  6. 36-month progression-free survival rate (IRC assessment)

    The proportion of subjects whose condition did not deteriorate or progress from the start of treatment to 36 months (IRC assessment)

    Time frame: From baseline to 36 months after treatment

  7. Objective response rate (Researcher Evaluation)

    The proportion of patients with tumor volume reduction reaching 30% is usually the sum of the proportions of complete response (CR) and partial response (PR). (Researcher Evaluation)

    Time frame: The period from baseline to the end of the trial is expected to be 32 months.

  8. Disease control rate(Researcher Evaluation)

    The proportion of cases that achieved remission (CR+PR) and disease stability (SD) after treatment, that is, the proportion of patients who did not experience disease progression (PD). (Researcher Evaluation)

    Time frame: The period from baseline to the end of the trial is expected to be 32 months.

  9. Duration of remission(Researcher Evaluation)

    The duration from the first significant shrinkage of the tumor to its subsequent enlargement/progression(Researcher Evaluation)

    Time frame: The period from baseline to the end of the trial is expected to be 32 months.

  10. Progression-free survival (Researcher Evaluation)

    The time from the start of treatment to disease progression or death for any reason (Researcher Evaluation)

    Time frame: The period from baseline to the end of the trial is expected to be 32 months.

  11. The 12-month progression-free survival rate(Researcher Evaluation)

    The proportion of subjects whose condition did not deteriorate or progress from the start of treatment to 12 months (Researcher Evaluation)

    Time frame: From baseline to 12 months after treatment

  12. 24-month progression-free survival rate(Researcher Evaluation)

    The proportion of subjects whose condition did not deteriorate or progress from the start of treatment to 24 months (Researcher Evaluation)

    Time frame: From baseline to 24 months after treatment

  13. 36-month progression-free survival rate (Researcher Evaluation)

    The proportion of subjects whose conditions did not deteriorate or progress from the start of treatment to 36 months(Researcher Evaluation)

    Time frame: From baseline to 36 months after treatment

  14. Overall survival

    The time of death from the start of treatment to any cause of death.

    Time frame: Baseline to death (estimated 48 months)

  15. Numbers of subject with the incidence and severity of adverse events (AE) and serious adverse events (SAE), as well as abnormal laboratory test indicators

    Numbers of subject with the incidence and severity of adverse events (AE) and serious adverse events (SAE) that occurred during the trial, as well as abnormal laboratory test indicators

    Time frame: The period from baseline to the end of the trial is expected to be 32 months.

07

Study locations

1 of 15 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2026 (actual). Primary completion is estimated for Dec 2028, 32 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Nov 2027 → Dec 2028 and completion Nov 2028 → Jun 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2026
First posted
Apr 23, 2026
StartActual
Apr 2, 2026
Primary completionEst.
Dec 2028was Nov 2027
CompletionEst.
Jun 2029was Nov 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 2027→Dec 2028
Nov 16, 2026
Study completion
Nov 2028→Jun 2029
Nov 16, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • ChangedBefore Laboratory tests meet the following standards:Now Laboratory tests meet the following standards (No hematopoietic stimulating factors have been used for correction within the past 14 days):
Exclusion criteria
  • EditedKnown to have spinal cord compression, carcinomatous meningitis, symptomatic brain metastases, or brain metastases with symptoms or symptoms controlled for less than 4 weeks of symptomatic/radiographic control.
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary completion Nov 2027→Dec 2028
    Study completion Nov 2028→Jun 2029
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore Laboratory tests meet the following standards:Now Laboratory tests meet the following standards (No hematopoietic stimulating factors have been used for correction within the past 14 days):
    Exclusion criteria
    • EditedKnown to have spinal cord compression, carcinomatous meningitis, symptomatic brain metastases, or brain metastases with symptoms or symptoms controlled for less than 4 weeks of symptomatic/radiographic control.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07548177
Responsible party
Sponsor
First posted
Apr 23, 2026
Start date
Apr 2, 2026
Primary completion
Dec 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Jiayong Liu, Doctor
Contact
liujiayong@aliyun.com
13641103227
Jing Chen, Doctor
Contact
chenjingunion@163.com
15807183251

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Benmelstobart · Catequentinib hydrochloride

Start the discussion